ABIVAX Société Anonyme (DB:2X1) - Stock Price, News & Analysis

2X1 Stock Overview

A clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. More details

2X1 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 66.09% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

ABIVAX Société Anonyme Competitors

Formycon

XTRA:FYB

€848.4m

Biotest

XTRA:BIO3

€1.4b

2invest

XTRA:2INV

€62.7m

Heidelberg Pharma

XTRA:HPHA

€102.1m

Price History & Performance

Summary of all time highs, changes and price drops for ABIVAX Société Anonyme
Historical stock prices
Current Share Price	€8.48
52 Week High	€15.26
52 Week Low	€8.04
Beta	1.42
11 Month Change	-7.93%
3 Month Change	-17.51%
1 Year Change	-6.92%
33 Year Change	-64.52%
5 Year Change	-25.61%
Change since IPO	-39.88%

Recent updates

Shareholder Returns

	2X1	DE Biotechs	DE Market
7D	-4.0%	-0.2%	0.8%
1Y	-6.9%	-16.9%	9.1%

Return vs Industry: 2X1 exceeded the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: 2X1 underperformed the German Market which returned 8.5% over the past year.

Price Volatility

Is 2X1's price volatile compared to industry and market?
2X1 volatility
2X1 Average Weekly Movement	6.6%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 2X1 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 2X1's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2013	62	Marc M. de Garidel	www.abivax.com

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

ABIVAX Société Anonyme Fundamentals Summary

How do ABIVAX Société Anonyme's earnings and revenue compare to its market cap?
2X1 fundamental statistics
Market cap	€516.39m
Earnings (TTM)	-€177.42m
Revenue (TTM)	€9.03m

57.2x

P/S Ratio

-2.9x

P/E Ratio

Is 2X1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2X1 income statement (TTM)
Revenue	€9.03m
Cost of Revenue	€0
Gross Profit	€9.03m
Other Expenses	€186.46m
Earnings	-€177.42m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.80
Gross Margin	100.00%
Net Profit Margin	-1,964.62%
Debt/Equity Ratio	87.9%

How did 2X1 perform over the long term?

See historical performance and comparison

2X1 Stock Overview

Rewards

Risk Analysis

ABIVAX Société Anonyme Competitors

XTRA:FYB

€848.4m

XTRA:BIO3

€1.4b

XTRA:2INV

€62.7m

XTRA:HPHA

€102.1m

Price History & Performance

Recent News & Updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

New major risk - Revenue and earnings growth

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

New major risk - Share price stability

New major risk - Revenue and earnings growth

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

New major risk - Revenue and earnings growth

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

No longer forecast to breakeven

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

No longer forecast to breakeven

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Insufficient new directors

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Forecast breakeven date moved forward to 2022

Insufficient new directors

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

No longer forecast to breakeven

Forecast to breakeven in 2021

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

New 90-day low: €20.80

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

New 90-day high: €29.40

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

New 90-day high: €21.45

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

New 90-day low: €17.24

First half earnings released

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

New 90-day low - €18.50

New 90-day low - €19.00

Shareholder Returns

Price Volatility

About the Company

ABIVAX Société Anonyme Fundamentals Summary

57.2x